Navigation Links
Pharmacopeia Nominates Novel Chemokine Receptor Antagonist for Development
Date:2/11/2008

HREF="mailto:ir_pr@pcop.com">ir_pr@pcop.com

This press release, and oral statements made with respect to information contained in this press release, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those which express plan, anticipation, intent, goal, contingency or future development and/or otherwise are not statements of historical fact. These statements are based upon management's current expectations and are subject to risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. These forward- looking statements include, but are not limited to, statements about the successful implementation of Pharmacopeia's strategic plans, Pharmacopeia's plans to develop PS031291, a product candidate from its chemokine receptor CCR1 program, Pharmacopeia's plans to develop PS433540, a product candidate from its DARA program, Pharmacopeia's Phase 2 and Phase 1 clinical studies with respect to PS433540, including timing and expected outcomes of such studies, Pharmacopeia's plans to develop PS178990, a product candidate from its SARM program, Pharmacopeia's Phase 1 clinical studies with respect to PS178990, including timing and expected outcomes of such studies, Pharmacopeia's estimates of the market opportunities for its product candidates, including PS433540, PS178990 and PS031291, Pharmacopeia's ability to successfully perform under its collaborations with Bristol-Myers Squibb, Cephalon, GlaxoSmithKline, Schering-Plough and Wyeth, Pharmacopeia's ability to build its pipeline of novel drug candidates through its own internally- funded drug discovery programs, third party collaborations and in-licensing, Pharmacopeia's ability to raise additional capital, Pharmacopeia's expectations concerning the development priorities of its collaborators, their ability to s
'/>"/>

SOURCE Pharmacopeia
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmacopeia to Present at BIO CEO & Investor Conference 2008
2. Pharmacopeia Announces Additional Positive Findings from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
3. Pharmacopeia Announces Third Quarter 2007 Financial Results
4. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
5. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
6. Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA)
7. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
8. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
9. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
10. Novel Small Molecule Therapy Shows Benefit for Anemic Patients Via Hydration of Red Blood Cells
11. CeNeRx BioPharma Announces Successful Completion of Phase l Clinical Program for Novel Antidepressant Agent Tyrima(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014  Unilife Corporation ("Unilife" ... announced today that it intends to release its financial ... ended June 30, 2014 after market trading ends on ... scheduled a conference call for 4:30 p.m. U.S. EDT ... at 6:30 a.m. AEST), to review the Company,s financial results, ...
(Date:8/29/2014)... Research and Markets has announced ... Market 2014-2018" report to their offering. ... that results in demyelination, axonal transection, and neurodegeneration. The ... by the immune system, which targets neurons within the ... disease in which the damage of the myelin sheath ...
(Date:8/29/2014)... 2014  Abaxis, Inc. (NasdaqGS: ABAX ), ... consumables to the medical, research and veterinary markets, announced ... Executive Officer, will present at the CL King 12 ... September 9, 2014 at 12:30 p.m. ET. The conference ... in New York City . ...
Breaking Medicine Technology:Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3Abaxis, Inc. to Present at CL King's 12th Annual Best Ideas Conference 2014 2
... 24 Sunridge International (OTC Bulletin Board: SNDZ ... month to have meetings with key brokers and funds.  The ... our company,s technology, and to facilitate funding for Sunridge to ... is a good time for this project," states G. Richard ...
... Corporation (Nasdaq: CLSN ), a leading ... U.S. Food and Drug Administration (FDA) has designated ... in combination with radiofrequency ablation (RFA), as a ... liposomal encapsulation of doxorubicin, is currently being evaluated ...
Cached Medicine Technology:Celsion Receives Fast Track Designation for ThermoDox® Development Program to Treat Primary Liver Cancer 2Celsion Receives Fast Track Designation for ThermoDox® Development Program to Treat Primary Liver Cancer 3Celsion Receives Fast Track Designation for ThermoDox® Development Program to Treat Primary Liver Cancer 4
(Date:8/29/2014)... USA (PRWEB) August 29, 2014 As reported ... Is Help (8/15), the process of admitting that you ... a struggle. The article acknowledges and highlights the fact that ... problem, you may be very overwhelmed by all of the ... is nearly impossible to sift through, it is still possible ...
(Date:8/29/2014)... Market Research Report on Global and ... and in-depth market survey on Global and Chinese ... basic information of Glass microfiber including its classification, ... global and China’s top manufacturers of Glass microfiber ... market share etc. , The report further analyzes ...
(Date:8/29/2014)... A recent article discusses the creation ... clothing store for men with gynecomastia, or male breasts, to ... their problem. Board-certified plastic surgeon Dr. Chasan is familiar with ... people only associate male breasts with men who are excessively ... of all ages, often starting in adolescence. Men with the ...
(Date:8/29/2014)... IL (PRWEB) August 29, 2014 Pursuing ... is set to unveil a stunning new design ... to company figures, the highly notable surrogacy platform has ... January. With over 13,000 visitors a month, the FindSurrogateMother.com ... mothers working toward one common goal — the precious ...
(Date:8/29/2014)... report released yesterday by the Mental Health Commission ... health training and education that police personnel receive. ... issue for Canada,s police community, and today,s report ... enforcement and people with mental illnesses," says Queen,s ... an interest in the area of police psychology. ...
Breaking Medicine News(10 mins):Health News:What to Know When Seeking Drug Addiction Help 2Health News:What to Know When Seeking Drug Addiction Help 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4Health News:New Bra Created for Men with Gynecomastia, But Will It Work? 2Health News:New Bra Created for Men with Gynecomastia, But Will It Work? 3Health News:FindSurrogateMother.com Set to Unveil Stunning New Design as Member Sign-ups Increase by 42% since January 2Health News:FindSurrogateMother.com Set to Unveil Stunning New Design as Member Sign-ups Increase by 42% since January 3Health News:Report advocates improved police training 2
... ... Michael Steele join Tea Party Support ( http://teapartysupport.com ) and the ... do whatever is necessary, including the use of any parliamentary device ... its tracks. ,Rush Limbaugh questioned Senate Minority Leader McConnell’s strategy ...
... , SAN DIEGO, Dec. 11 ... of post-secondary education services focused on providing higher access to ... graduate school specializing in psychology programs at the master,s and ... in Career Management and Counseling. , This specialization responds ...
... NEW YORK, Dec. 11 WebMD Health Corp. (Nasdaq: ... offer to purchase up to 5,700,000 shares of its common ... at 5:00 p.m., New York City time on December 10, ... Transfer & Trust Company, the Depositary for the tender offer, ...
... December 11 2009 (Portland, Ore.) More than 10 ... at risk for developing diabetes during pregnancy, according to a ... in the December issue of the Ethnicity and Disease ... women,s gestational diabetes risk is one-third higher than averageand more ...
... , ... Board legally recovers the books and records of U.S. Shanghai Chemical Corporation from Chinese Principals! ... (PRWEB) December 11, 2009 ... Axxexs Capital, Inc. was acquired by a Chinese chemical company in a reverse merger. Principals ...
... ... ... do not believe that they know much about depression , but are highly aware of ... National Alliance on Mental Illness (NAMI)., , ,See full survey results at http://www.nami.org/depression , ...
Cached Medicine News:Health News:Rush Limbaugh & Michael Steele Join Tea Party Support & Social Security Institute-Demand GOP Senate Stop ObamaCare by Any Means Possible 2Health News:Rush Limbaugh & Michael Steele Join Tea Party Support & Social Security Institute-Demand GOP Senate Stop ObamaCare by Any Means Possible 3Health News:Bridgepoint Education's University of the Rockies Introduces New Master of Arts Specialization in Career Management and Counseling 2Health News:WebMD Health Corp. Announces Preliminary Results of Its Tender Offer 2Health News:WebMD Health Corp. Announces Preliminary Results of Its Tender Offer 3Health News:Chinese-American and Korean-American women at highest risk for diabetes in pregnancy 2Health News:Chinese-American and Korean-American women at highest risk for diabetes in pregnancy 3Health News:New Board Gains Control of U.S. Shanghai Chemical Corporation 2Health News:Depression Survey: Implications for Diverse Communities 2Health News:Depression Survey: Implications for Diverse Communities 3
1 x 2 teeth, cross serrated 5 mm 60 degree angled platform. Round knurled handle with polished finish....
Oval solid 16 mm wide lower plate. Open upper plate with inside dimensions 12 mm x 14 mm. Cross action serrated handle with polished finish....
Oval solid 15 mm wide lower plate. Open upper plate with inside dimensions 11 mm x 8 mm. Serrated handle with locking thumb screw and polished finish....
Slender 4.5 mm long rounded platform. Serrated handle with polished finish....
Medicine Products: